Xanthon Inc. has received a patent that will help the company commercialize and manufacture the technology behind its DNA/RNA analysis instrument, according to reports in LocalBusiness.com,. Called the Xanthon Expression Analysis System, Xanthon's DNA/RNA tool will be sold starting next year to pharmaceutical companies that will use it to analyze DNA/RNA to discover targets for drugs. Xanthon, which is based in the RTP, plans to test its genetic analysis equipment at beta sites starting early next year. Company officials said the patent Xanthon just received from the U.S. Patent and Trademark Office describes the method of manufacturing the Expression Analysis System's technology.
CED News
« CP&L Completes Acquisition of Florida Progress | Main | Arsenal Digital Solutions, Peak 10 Ink Three-Year Deal »